These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10206072)

  • 1. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study.
    Makris A; Powles TJ; Allred DC; Ashley SE; Trott PA; Ormerod MG; Titley JC; Dowsett M
    Breast Cancer Res Treat; 1999 Jan; 53(1):51-9. PubMed ID: 10206072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.
    Makris A; Powles TJ; Dowsett M; Osborne CK; Trott PA; Fernando IN; Ashley SE; Ormerod MG; Titley JC; Gregory RK; Allred DC
    Clin Cancer Res; 1997 Apr; 3(4):593-600. PubMed ID: 9815725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytological evaluation of biological prognostic markers from primary breast carcinomas.
    Makris A; Allred DC; Powles TJ; Dowsett M; Fernando IN; Trott PA; Ashley SE; Ormerod MG; Titley JC; Osborne CK
    Breast Cancer Res Treat; 1997 May; 44(1):65-74. PubMed ID: 9164679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma.
    Chang J; Ormerod M; Powles TJ; Allred DC; Ashley SE; Dowsett M
    Cancer; 2000 Dec; 89(11):2145-52. PubMed ID: 11147583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer.
    Chang J; Powles TJ; Allred DC; Ashley SE; Clark GM; Makris A; Assersohn L; Gregory RK; Osborne CK; Dowsett M
    J Clin Oncol; 1999 Oct; 17(10):3058-63. PubMed ID: 10506600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response.
    Makris A; Powles TJ; Allred DC; Ashley S; Ormerod MG; Titley JC; Dowsett M
    Breast Cancer Res Treat; 1998 Mar; 48(1):11-20. PubMed ID: 9541185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
    von Minckwitz G; Sinn HP; Raab G; Loibl S; Blohmer JU; Eidtmann H; Hilfrich J; Merkle E; Jackisch C; Costa SD; Caputo A; Kaufmann M;
    Breast Cancer Res; 2008; 10(2):R30. PubMed ID: 18380893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
    Kariya S; Ogawa Y; Nishioka A; Moriki T; Ohnishi T; Ito S; Murata Y; Yoshida S
    Radiat Med; 2005 May; 23(3):189-94. PubMed ID: 15940066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer.
    Bottini A; Berruti A; Bersiga A; Brizzi MP; Allevi G; Bolsi G; Aguggini S; Brunelli A; Betri E; Generali D; Scaratti L; Bertoli G; Alquati P; Dogliotti L
    Clin Cancer Res; 2002 Jun; 8(6):1816-21. PubMed ID: 12060622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer.
    Burcombe RJ; Makris A; Richman PI; Daley FM; Noble S; Pittam M; Wright D; Allen SA; Dove J; Wilson GD
    Br J Cancer; 2005 Jan; 92(1):147-55. PubMed ID: 15611798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcl-2 expression on fine-needle aspirates from primary breast carcinoma: correlation with other biologic factors.
    Bozzetti C; Nizzoli R; Naldi N; Guazzi A; Camisa R; Bella MA; Cocconi G
    Cancer; 1999 Aug; 87(4):224-30. PubMed ID: 10455211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers.
    Enomoto Y; Morimoto T; Nishimukai A; Higuchi T; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Nomura T; Takeda M; Watanabe T; Hirota S; Miyoshi Y
    Int J Clin Oncol; 2016 Apr; 21(2):254-261. PubMed ID: 26338270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer.
    Daidone MG; Veneroni S; Benini E; Tomasic G; Coradini D; Mastore M; Brambilla C; Ferrari L; Silvestrini R
    Int J Cancer; 1999 Dec; 84(6):580-6. PubMed ID: 10567902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
    Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
    J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
    Iwata H; Masuda N; Sagara Y; Kinoshita T; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Tsuda H; Hayashi N; Noguchi S
    Cancer; 2013 Feb; 119(4):704-13. PubMed ID: 22972694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
    Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.
    Nishimura R; Osako T; Okumura Y; Hayashi M; Arima N
    Breast Cancer; 2010 Oct; 17(4):269-75. PubMed ID: 19730975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the results of immunocytochemical assays for biologic variables on preoperative fine-needle aspirates and on surgical specimens of primary breast carcinomas.
    Nizzoli R; Bozzetti C; Naldi N; Guazzi A; Gabrielli M; Michiara M; Camisa R; Barilli A; Cocconi G
    Cancer; 2000 Feb; 90(1):61-6. PubMed ID: 10692218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
    J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
    Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
    Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.